LOS ANGELES, CA--(Marketwire -12/14/11)- BioSig Technologies, Inc, a medical device company developing superior clinical solutions for diagnoses and treatments of abnormal heart rhythms, today announced that Jeffrey O'Donnell has joined the Company's Board of Directors.
Jeffrey O'Donnell commented, "I look forward to assisting the BioSig team develop a new standard of care with their game changing technology platform." He continued, "I believe PURE will enhance EP ablation procedures by increasing outcomes for patients and decreasing cost to the healthcare system."
Mr. O'Donnell brings 28 years of experience in the healthcare industry in sales, marketing and management. Currently, Mr. O'Donnell is a Venture Partner of Biostar Ventures, a venture capital firm investing primarily in early stage medical device companies. Previously he was the CEO of Embrella Cardiovascular sold to Edwards Life Sciences earlier this year. Mr. O'Donnell has been the CEO of six medical device companies and held several senior management positions at Boston Scientific, Guidant Corporation and Johnson & Johnson.
In 2011 Mr. O'Donnell was named Greater Philadelphia Emerging Entrepreneur of the Year by Ernst & Young and in 2005 he was named Life Science CEO of the year by Eastern Technology Council.
Kenneth Londoner, CEO of BioSig, added, "We are delighted to have Jeffrey O'Donnell join our board. He brings a wealth of experience in the medical device arena and will be an invaluable asset on our board as we establish ourselves as an innovator in the electrophysiology community."
About BioSig Technologies:
BioSig Technologies is a medical device company developing unique clinical solutions for diagnoses and treatments of abnormal heart rhythms (arrhythmias). BioSig's PURE (Precise Uninterrupted Real-time evaluations of Electrograms) platform is designed to assist electrophysiologists during the termination of arrhythmias by cardiac ablation. PURE empowers electrophysiologists to make crucial clinical decisions in real time by providing information unobtainable with any other equipment presently in the electrophysiology (EP) lab. The Company is collaborating with physicians from the world-renowned Texas Cardiac Arrhythmia Institute (TCAI) in Austin, Texas.